Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Gains from Sales and Divestitures: 2023-2025

Historic Gains from Sales and Divestitures for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $71.8 million.

  • BioLineRx's Gains from Sales and Divestitures rose 108.71% to $71.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $71.8 million, marking a year-over-year increase of 108.71%. This contributed to the annual value of $38.1 million for FY2024, which is 21.50% up from last year.
  • Latest data reveals that BioLineRx reported Gains from Sales and Divestitures of $71.8 million as of Q2 2025, which was up 14.78% from $62.6 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Gains from Sales and Divestitures registered a high of $71.8 million during Q2 2025, and its lowest value of $27.1 million during Q1 2023.
  • Its 3-year average for Gains from Sales and Divestitures is $38.7 million, with a median of $32.9 million in 2023.
  • Data for BioLineRx's Gains from Sales and Divestitures shows a peak YoY spiked of 108.71% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows BioLineRx's Gains from Sales and Divestitures stood at $31.4 million in 2023, then grew by 21.50% to $38.1 million in 2024, then skyrocketed by 108.71% to $71.8 million in 2025.
  • Its Gains from Sales and Divestitures stands at $71.8 million for Q2 2025, versus $62.6 million for Q1 2025 and $38.1 million for Q4 2024.